Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm
Overview
Authors
Affiliations
Objective: During the natural course of multiple sclerosis (MS), the brain is exposed to aging as well as disease effects. Brain aging can be modeled statistically; the so-called "brain-age" paradigm. Here, we evaluated whether brain-predicted age difference (brain-PAD) was sensitive to the presence of MS, clinical progression, and future outcomes.
Methods: In a longitudinal, multicenter sample of 3,565 magnetic resonance imaging (MRI) scans, in 1,204 patients with MS and clinically isolated syndrome (CIS) and 150 healthy controls (mean follow-up time: patients 3.41 years, healthy controls 1.97 years), we measured "brain-predicted age" using T1-weighted MRI. We compared brain-PAD among patients with MS and patients with CIS and healthy controls, and between disease subtypes. Relationships between brain-PAD and Expanded Disability Status Scale (EDSS) were explored.
Results: Patients with MS had markedly higher brain-PAD than healthy controls (mean brain-PAD +10.3 years; 95% confidence interval [CI] = 8.5-12.1] versus 4.3 years; 95% CI = 2.1 to 6.4; p < 0.001). The highest brain-PADs were in secondary-progressive MS (+13.3 years; 95% CI = 11.3-15.3). Brain-PAD at study entry predicted time-to-disability progression (hazard ratio 1.02; 95% CI = 1.01-1.03; p < 0.001); although normalized brain volume was a stronger predictor. Greater annualized brain-PAD increases were associated with greater annualized EDSS score (r = 0.26; p < 0.001).
Interpretation: The brain-age paradigm is sensitive to MS-related atrophy and clinical progression. A higher brain-PAD at baseline was associated with more rapid disability progression and the rate of change in brain-PAD related to worsening disability. Potentially, "brain-age" could be used as a prognostic biomarker in early-stage MS, to track disease progression or stratify patients for clinical trial enrollment. ANN NEUROL 2020 ANN NEUROL 2020;88:93-105.
Exploratory analysis of biological age measures in a remyelination clinical trial.
McMurran C, de Meo E, Cunniffe N, Brown J, Prados F, Kanber B Brain Commun. 2025; 7(1):fcaf032.
PMID: 40008332 PMC: 11852336. DOI: 10.1093/braincomms/fcaf032.
Spatial transcriptomic clocks reveal cell proximity effects in brain ageing.
Sun E, Zhou O, Hauptschein M, Rappoport N, Xu L, Navarro Negredo P Nature. 2024; 638(8049):160-171.
PMID: 39695234 PMC: 11798877. DOI: 10.1038/s41586-024-08334-8.
De Bonis M, Fasano G, Lombardi A, Ardito C, Ferrara A, Di Sciascio E Brain Inform. 2024; 11(1):33.
PMID: 39692946 PMC: 11655902. DOI: 10.1186/s40708-024-00244-9.
Exploring the role of sex hormones and gender diversity in multiple sclerosis.
Nesbitt C, van der Walt A, Butzkueven H, Cheung A, Jokubaitis V Nat Rev Neurol. 2024; 21(1):48-62.
PMID: 39658653 DOI: 10.1038/s41582-024-01042-x.
Pontillo G, Prados F, Colman J, Kanber B, Abdel-Mannan O, Al-Araji S Neurology. 2024; 103(10):e209976.
PMID: 39496109 PMC: 11540460. DOI: 10.1212/WNL.0000000000209976.